공시 • Dec 05
Vaxil Bio Ltd. announced that it has received CAD 0.14 million in funding On December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants. 공시 • Dec 04
Vaxil Bio Ltd. Announces Board Changes Vaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters. 공시 • Oct 30
Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in funding Vaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws. 공시 • Apr 04
Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit Committee Vaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director). 공시 • Jan 17
Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.
Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025. 공시 • Oct 07
Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024 Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024. 공시 • May 28
Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. 공시 • Mar 06
Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration.
The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.
Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024. 공시 • Jan 11
Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction. Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration.
The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. 공시 • Jan 05
Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOX VAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.